Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

计划入组 10 人 · 首次发布于 2025 年 9 月 15 日

Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy

计划入组 18 人 · 首次发布于 2022 年 8 月 23 日

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

计划入组 130 人 · 首次发布于 2025 年 12 月 10 日

CPL-200-075

Dapagliflozin(Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris, Ebymect)

C₂₁H₂₅ClO₆ · Rx

Sodium Lactate and Glucose

Rx

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

Study Shows SGLT2 Inhibitors Improve Renal Function in Non-Diabetic CKD Patients

Dapagliflozin Approved by FDA to Reduce Cardiovascular and Renal Risks in CKD Patients

SGLT-2 Inhibitors Linked to Reduced Dementia Risk in Type 2 Diabetes Study